Pfizer Inc. PFE on Wednesday reported positive Phase 2 data for its investigational 25-valent pneumococcal conjugate vaccine candidate. The study showed strong immune responses in infants compared ...

Earlier in May 2026, Pfizer reported positive Phase 2 results for its investigational 25‑valent pneumococcal conjugate vaccine in infants, showing strong immune responses versus PREVNAR 20 and ...

Pfizer (PFE) on Wednesday announced that it has begun a Phase 3 trial for its 25-valent pneumococcal vaccine, PF-07872412 (25vPnC), for infants after the shot outperformed its pneumococcal 20-valent ...

May 20 () - Pfizer said on Wednesday its experimental pneumococcal vaccine showed significantly stronger immune response than its current ‌shot, including up to 15-fold higher antibody levels against ...

Vaxcyte recently completed enrollment for three Phase 3 adult clinical trials of its VAX-31 pneumococcal vaccine candidate, along with a Phase 2 VAX-31 infant study, and outlined plans to start a ...

The next-generation version of Pfizer'sPFE $6 billion pneumococcal vaccine franchise topped its predecessor in a midstage study, the S&P 500 drug giant said Wednesday. Pfizer compared four doses of ...

Sept 11 (Reuters) - Merck's (MRK.N), opens new tab pneumococcal vaccine triggered immune responses in children and teens who are at higher risk of serious illness in a late-stage study, the drugmaker ...

India's patent office has granted Pfizer a patent on its pneumococcal conjugate vaccine (PCV), known as Prevnar 13, after Doctors Without Borders (MSF) challenged the patent’s claims. The decision ...